

CNS DISEASES WORLD SUMMIT 2014

Includes the two co-located conferences:

- 7TH CNS PARTNERING & DEAL-MAKING
- 8TH NEURODEGENERATIVE CONDITIONS RESEARCH & DEVELOPMENT

SEPTEMBER 18-19, 2014 • SAN FRANCISCO, CA

Gold Sponsor



Media Partners



Visit www.gtcbio.com for more information!

ABOUT

The [CNS Diseases World Summit 2014](#) has become a meeting place for all stakeholders in the neuroscience field to discuss the current state of research and drug development. The Summit consists of two parallel conferences, which will provide a targeted program for those in licensing and business development and for those in research: the [CNS Partnering & Deal-Making Conference](#) and the [Neurodegenerative Conditions Research & Development Conference](#), respectively. Colleagues from industry, academia, patient advocacy groups, and government will gather to discuss private/public partnerships, rare CNS diseases, translational biomarkers, and much more.

CALL FOR PAPERS

To be considered for a short oral presentation at the **8th Neurodegenerative Conditions Research & Development Conference**, please submit an abstract by **August 18, 2014**. Selected presentations will be based on quality of abstract and availability. Selected abstracts will be notified via email or telephone 2-3 weeks before the conference. Presentation slots fill up fast so please submit your abstract soon.

Click [here](#) to submit an abstract.

COMPANY PRESENTATIONS

Companies interested in presenting their programs in front of decision makers in the CNS field and initiating strategic alliances can submit an abstract proposal [here](#).

Submissions will be reviewed by the advisory committee and accepted presentations will be contacted by the event organizers.

SPONSORSHIP AND EXHIBITOR OPPORTUNITIES

Connect with high level professionals and renowned scientists in academia in an intimate and highly interactive environment. We are expecting over 150 attendees for the entire CNS Diseases World Summit 2014.

- Sponsors/exhibitors have the option to receive the delegate list a week before and a week after the conference.
- Exhibit space is shared between all conferences, providing sponsors/exhibitors access to delegates at all conferences. Exhibitors are located in the same room where all networking functions take place. The coffee, snack stations, breakfast, and reception all occur in this room.
- Your corporate logo will be placed on the cover page of the conference brochures, the USB proceedings given to all conference delegates, and on the presentation screen during all breaks to enhance your company's visibility at the event. Your logo will also be placed on the conference website agenda linked to your website.

For sponsorship and exhibit opportunities, please contact:

Amber Kempf
Account Executive
amber.kempf@gtcbio.com

2014 SPONSOR

GOLD



AGENDA AT A GLANCE

Monday, July 7, 2014

7:00a *Registration & Continental Breakfast*

7:55a *Welcoming & Opening Remarks*

Plenary Keynote Session

Challenges and Opportunities in CNS Therapeutics: Making Molecules that Matter

Darryle Schoepp, Vice President and Therapeutic Area Head, Neuroscience, Early Development & Discovery Sciences, Merck

8:00a
Daniel Grau, President, Heptares Therapeutics

9:20a *Morning Networking & Refreshment Break*

8th Neurodegenerative Conditions Research & Development

Session:
Novel Therapeutics and Approaches in Alzheimer's Disease

9:50a

7th CNS Partnering & Deal-Making

Session:
New Approaches to Funding in the CNS

Panel Discussion:
Investment Opportunities with Venture Capital

Panel Discussion:
Early-Stage CNS Partnering and Deals

12:20p *Lunch on Your Own*

Session:
New Approaches and Treatments in Neurodegenerative
and Neuropsychiatric Conditions

Oral Presentations

2:00p

Session:
Private/Public Partnerships in the CNS

Panel Discussion:
Private/Public Partnerships to Advance Research

Panel Discussion:
The Unique Role of Patient Advocacy Groups in
Neuroscience

3:35p *Afternoon Networking & Refreshment Break*

Joint Session Rare CNS Diseases

CNS Orphans and Disease Sub-segments: the Road Less Traveled

Ginger Johnson, Senior Partner, **Defined Health**

Targets of Histone deacetylase (HDAC) inhibition: Relevance to Neurodegenerative Conditions
Elizabeth Thomas, Associate Professor, Molecular and Cellular Neuroscience, The Scripps Research Institute

4:15p

Target ALS, The Roadmap for ALS Treatments
Manish Raisinghani, Executive Director, **Target ALS**

Speaker TBA

6:15p *Evening Networking Reception & Poster Session*

All times are approximate and subject to changes without notice

AGENDA AT A GLANCE

Tuesday, July 8, 2014

7:30a

Continental Breakfast

8th Neurodegenerative Conditions Research & Development

7th CNS Partnering & Deal-Making

8:00a

Session:
Drug Mechanisms & Treatments in Parkinson's Disease

Session:
Partnering & Licensing in the CNS

Panel Discussion:
What Sells Big Pharma in CNS Diseases?

Panel Discussion:
CNS Licensing Strategies

Panel Discussion:
New Partnership Structures in CNS R&D

10:30a

Morning Networking & Refreshment Break

Session:
Biomarkers: Translation from Discovery to Clinical

Session:
Up & Coming Trends and Other Considerations in Neuroscience

Panel Discussion:
Regulatory Considerations and Challenges in the CNS

Company Presentations Available

11:00a

12:40p

Lunch Provided by GTC

Plenary Keynote Session

2:00p

Bridging Discovery Gaps for Neurodegenerative Disorders with Human Genomics to Therapeutics with Patient-derived Stem Cells, Robotic Imaging, and Machine Learning

Steven Finkbeiner, Director, Taube-Koret Center for Neurodegenerative Disease Research, University of California, San Francisco

Speaker TBA

3:20p

Conferences Conclude

All times are approximate and subject to changes without notice

KEYNOTE SPEAKERS



Bridging Discovery Gaps for Neurodegenerative Disorders with Human Genomics to Therapeutics with Patient-derived Stem Cells, Robotic Imaging, and Machine Learning

Steven Finkbeiner, Director, Taube-Koret Center for Neurodegenerative Disease Research, **University of California, San Francisco**

Dr. Finkbeiner studies the molecular mechanisms that are responsible for learning, memory and neurodegeneration. He is best known for his pioneering work on neurodegenerative diseases. He invented a new form of imaging that has helped unravel cause-and-effect relationships in neurodegenerative diseases and used this new technology to resolve a long-standing puzzle in Huntington's disease. That report became the most-cited paper in neuroscience in the decade in which it was published.

Developing faithful models of neurodegenerative disease is a critical step in the process of understanding their causes and finding effective therapies. Cellular reprogramming and patient-derived induced pluripotent stem cells has made it possible to make models of neurodegenerative disease using skin cells from affected patients. Already, these models are being used at Gladstone to investigate the causes of disease and to test potential therapies. With the help of Bay Area philanthropists, Dr. Finkbeiner established the Taube/Koret Center to accelerate development of drug therapies for neurodegenerative disease.



Daniel Grau, President, **Heptares Therapeutics**

Daniel Grau is a biotech executive with over 15 years of experience developing, partnering, and commercialising new medicines and life science technologies. He joined Heptares as President in 2011 and had served previously as a Senior Advisor focused on business development and strategy since 2010. Previously, Dan served as President and CEO of Cortria Corporation, a venture-backed, clinical-stage company focused in cardiovascular disease, and as Chief Operating Officer of CombinatoRx, Inc., a public biotech company (today Zalicus) focused primarily in pain and inflammation. Earlier in his career, he worked with Pharmacia Corporation (now Pfizer) as a management consultant focused on the commercialisation of Celebrex™, Mirapex™ and Detrol™, and was Director of Marketing and Business Development for a healthcare information technology start-up. Dan earned his BA with High Honors in English from Davidson College, where he held a Charles A. Dana Honor Scholarship, and received his MPhil in Philosophy from Yale University, where he held an Andrew J. Mellon Fellowship in the Humanities.



Challenges and Opportunities in CNS Therapeutics: Making Molecules that Matter

Darryle Schoepp, Vice President and Therapeutic Area Head, Neuroscience, Early Development and Discovery Sciences, **Merck**

Darryle D. Schoepp serves as Senior Vice President and Franchise Head of Merck Research Laboratories. Dr. Schoepp served as Senior Vice President and Director of Neuroscience Drugs of Merck & Co. Inc. since March 2007. Dr. Schoepp has 20 years in neuroscience discovery research at Eli Lilly and Company, where for the past three years he has served as Vice President and overall global Head of neuroscience research and early clinical investigation. Dr. Schoepp serves on the Board of Publication Trustees for ASPET and as an Executive Editor for the journal Neuropharmacology. In 2002, Dr. Schoepp was honored with the Pharmacia / American Society for Experimental Therapeutics (ASPET) Award for Experimental Therapeutics for his research on the experimental therapeutics of metabotropic glutamate receptors. Dr. Schoepp received his Bachelor's degree in Pharmacy from North Dakota State University and his doctoral degree in Pharmacology and Toxicology from West Virginia University. He conducted postdoctoral research in Pharmacology and Toxicology at the University of Kansas. He is a member of the American College of Neuropsychopharmacology (ACNP).

8th Neurodegenerative Conditions Research & Development Conference

DISTINGUISHED PANELISTS, SPEAKERS AND MODERATORS



Session: Novel Therapeutics and Approaches in Alzheimer's Disease

Gai Ayalon
Junior Investigator
Genetech



Session: Biomarkers: Translation from Discovery to Clinical

Johan Luthman
VP Neuroscience Clinical Development
Eisai Pharmaceuticals



Session: Biomarkers: Translation from Discovery to Clinical

Robert Bowser
Principal Investigator and Professor, Divisions of Neurology and Neurobiology Director
Barrow Neurological Institute



ADS-5102 (Amantadine ER) for CNS Disorders: New Uses for an Old Drug

Jack Nguyen
Senior Director, Research
Adamas Pharmaceuticals



Session: Novel Therapeutics and Approaches in Alzheimer's Disease

Jonathan Brothie
Director
Atuka Inc.



Target ALS, The Roadmap for ALS Treatments

Manish Raisinghani
Executive Director
Target ALS



Targeting Misfolded Proteins In Vitro and In Vivo with Immunoglobulin-General Amyloid Interaction Motif (Ig-GAIM) Molecules

Richard Fisher
Chief Scientific Officer
Neurophage



Therapeutic Targeting of Neuronal Apoptosis in Parkinson's Disease

Steven I. Reed
Professor, Cell and Molecular Biology
The Scripps Research Institute



Using Known Risk Factors in Alzheimer's Disease for Drug Discovery Strategy and Patient Stratification

Marcie Glicksman
Co-Director, Laboratory for Drug Discovery
Harvard NeuroDiscovery Center



M1 PAMs in Schizophrenia

Jerri Rook
Instructor, Department of Pharmacology
Vanderbilt Center for Neuroscience Drug Discovery



Session: Novel Therapeutics and Approaches in Alzheimer's Disease

Todd E. Golde
Professor, Neuroscience
University of Florida



Heritable Alterations in the Epigenome in Response to Cocaine

Ghazaleh Sadri-Vakili
Assistant Professor, Neurology
Harvard Medical School

8th Neurodegenerative Conditions Research & Development Conference

DISTINGUISHED PANELISTS, SPEAKERS AND MODERATORS (cont.)



siRNA-Mediated Reduction in Midbrain Alpha-Synuclein Levels for Parkinson's Disease Treatment

Richard C. Grondin
Assistant Professor
University of Kentucky Medical Center



Targets of Histone deacetylase (HDAC) inhibition: Relevance to Neurodegenerative Conditions

Elizabeth Thomas
Associate Professor, Molecular and Cellular Neuroscience
The Scripps Research Institute



Session: Biomarkers: Translation from Discovery to Clinical

Warren Hirst
Associate Research Fellow, Biology
Pfizer



Session: Drug Mechanisms & Treatments in Parkinson's Disease

Mark Varney
Chief Scientific Officer
Neurolinx Inc.



CNS Orphans and Disease Sub-segments: The Road Less Traveled

Ginger Johnson
Vice President
Defined Health



BACE1 Inhibition as a Therapeutic Strategy for Alzheimer's Disease

Robert Vassar
Professor
Northwestern University



Structural Mechanisms and Small Molecule Compounds Regulating Parkin Enzyme Activation

Jennifer Johnston
Vice President, Exploratory Research
Elan Pharmaceuticals



Unstoppable Mitochondria in Parkinson's Disease

Xinnan Wang
Assistant Professor, Neurosurgery
Stanford University

7th CNS Partnering & Deal-Making Conference

DISTINGUISHED PANELISTS, SPEAKERS AND MODERATORS



Panel Discussion: What Sells Big Pharma in CNS Diseases?

Bob Bagdorf
VP, Worldwide Business Development
Pfizer



NINDS Launches New Programs to Support Therapeutic and Device Discovery & Development

Rajesh Ranganathan
Director, Translational Research
National Institutes of Health



Panel Discussion: Early-Stage CNS Partnering and Deals

Steven Bartz
Director, Business Development
Merck Worldwide Licensing and External Research



Session:

Deborah Rathjen
CEO & Managing Director
Bionomics



Session: Private/Public Partnerships in the CNS

Elona Baum
General Counsel and Vice President of Business Development
California Institute for Regenerative Medicine (CIRM)



Panel Discussion: Investment Opportunities with Venture Capital

Kiran Reddy
Associate Partner
Third Rock Ventures



Panel Discussion: Regulatory Considerations and Challenges in the CNS

Jessica Beaver
Senior Director, Regulatory Affairs & Quality Compliance
Targacept



Panel Discussion: New Partnership Structures in CNS R&D

John Renger
Executive Director, Neuroscience Early Discovery
Merck



Panel Discussion: CNS Licensing Strategies

Woody Bryan
Vice President, Business Development
Supernus



Panel Discussion: CNS Licensing Strategies

Kenneth J. Rhodes
Former Vice President, Neurology Discovery
Biogen-Idec



Session: New Approaches to Funding in the CNS

Sohini Chowdhury
Senior Vice President, Research Partnerships
Michael J. Fox Foundation



Session: Partnering & Licensing in the CNS

Fernando Salles
Vice President, Global Business Development
Teva Pharmaceuticals



Panel Discussion: Regulatory Considerations and Challenges in the CNS

David Clissold
Attorney
Hyman, Phelps & McNamara



Panel Discussion: Private/Public Partnerships to Advance Research

James Schaeffer
Executive Director, Worldwide Licensing and External Research
Merck

7th CNS Partnering & Deal-Making Conference

DISTINGUISHED PANELISTS, SPEAKERS AND MODERATORS (cont.)



Panel Discussion: The Unique Role of Patient Advocacy Groups in Neuroscience

Mark Day
Global Head, Genetic Diseases and
Immunovirology
Bristol-Myers Squibb



Session: New Approaches to Funding in the CNS

Jamie Driscoll
Project Officer
NIMH, NIH



Panel Discussion: New Partnership Structures in CNS R&D

Beth Fordham-Meier
Principal & Founder
NovoCreation Consulting



CNS Orphans and Disease Sub-segments: the Road Less Traveled

Ginger Johnson
Vice President
Defined Health



Panel Discussion: Investment Opportunities with Venture Capital

Jeff Karan
Senior Partner
Woodside Capital Partners



Panel Discussion: CNS Licensing Strategies

Jay Kranzler
Global Head, Neuroscience External R&D
Innovation
Pfizer



Panel Discussion: Investment Opportunities with Venture Capital

Graeme Martin
President & CEO
Takeda Ventures



Panel Discussion: Early-Stage CNS Partnering and Deals

Kevin Pong
Director, Business Development
Sunovion



Panel Discussion: Early-Stage CNS Partnering and Deals

Guy Seabrook
Vice President, Neuroscience Innovation
J&J California Innovation Center



Panel Discussion: What Sells Big Pharma in CNS Diseases?

Virginia Smith-Swintosky
Senior Director, Scientific Licensing, Neuroscience
Johnson & Johnson



Panel Discussion: New Partnership Structures in CNS R&D

Carmine Stengone
Chief Executive Officer
Afraxis



Panel Discussion: CNS Licensing Strategies

Martin Tolar
Founder, President & CEO
Alzheon, Inc.



Session: Up & Coming Trends and Other Considerations in Neuroscience

Harry Tracy
President
NI Research Inc



Session: Up & Coming Trends and Other Considerations in Neuroscience

Jamie Tyler
CSO
Neurotrek



Panel Discussion: What Sells Big Pharma in CNS Diseases?

Shafiq Virani
Global Head Neuroscience, Ophthalmology
& Rare Disease Partnering
Hoffmann-La Roche

CONFERENCE DETAILS

REGISTRATION

Early Registration Discounts:

20% until July 18, 2014

10% until August 18, 2014

Register for 2 the 3rd goes FREE with coupon code: **RCDVB**To register online, visit: <https://www.gtcbio.com/register/cns-diseases-world-summit>

	Commercial	Academic / Govt	Student
CNS Diseases World Summit	1995.00	1045.00	895.00
Individual Conferences	1795.00	845.00	695.00

QUICK REGISTRATION - FAX TO (626) 466-4433

First Name: _____ Last Name: _____

Title: _____ Company: _____

Discount Coupon Code: _____

Card #: _____ Exp. Date: _____ CSV #: _____

Cardholder Name: _____

Signature: _____

Billing Address: _____

City: _____ State: _____ Zip: _____

VENUE

Sheraton Fisherman's Wharf Hotel2500 Mason Street
San Francisco, CA 94133
(415) 362-5500**Discounted Group Rate: \$269.00 per night****Discount Deadline: September 1, 2014**

Mention GTC to receive the group rate.

Online Reservations:

<https://www.starwoodmeeting.com/Book/CNSDISWORLD>

PROCEEDINGS

If you are unable to attend the conference you can purchase the proceedings by downloading the order form [here](#). Fill out the order form and fax it to 1 (626) 433-4433 or email it to proceedings@gtcbio.com.